Announcement • Jun 30
Pulike Biological Engineering, Inc. to Report First Half, 2026 Results on Aug 25, 2026 Pulike Biological Engineering, Inc. announced that they will report first half, 2026 results on Aug 25, 2026 Declared Dividend • Jun 15
Dividend of CN¥0.40 announced Shareholders will receive a dividend of CN¥0.40. Ex-date: 16th June 2026 Payment date: 16th June 2026 Dividend yield will be 5.7%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not covered by earnings (120% earnings payout ratio) nor is it covered by cash flows (102% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 33% to bring the payout ratio under control. EPS is expected to grow by 53% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Price Target Changed • May 04
Price target decreased by 13% to CN¥15.66 Down from CN¥17.99, the current price target is an average from 2 analysts. New target price is 31% above last closing price of CN¥11.97. Stock is down 12% over the past year. The company is forecast to post earnings per share of CN¥0.58 for next year compared to CN¥0.54 last year. Reported Earnings • Apr 29
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥0.54 (up from CN¥0.27 in FY 2024). Revenue: CN¥1.09b (up 4.5% from FY 2024). Net income: CN¥185.0m (up 99% from FY 2024). Profit margin: 17% (up from 8.9% in FY 2024). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 8.0%. Earnings per share (EPS) exceeded analyst estimates by 1.9%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Announcement • Apr 29
Pulike Biological Engineering, Inc., Annual General Meeting, May 21, 2026 Pulike Biological Engineering, Inc., Annual General Meeting, May 21, 2026, at 14:00 China Standard Time. Location: 2F, No. 15, Zhenghe Road, Luolong District, Luoyang, Henan China Announcement • Mar 30
Pulike Biological Engineering, Inc. to Report Q1, 2026 Results on Apr 29, 2026 Pulike Biological Engineering, Inc. announced that they will report Q1, 2026 results on Apr 29, 2026 Announcement • Dec 26
Pulike Biological Engineering, Inc. to Report Fiscal Year 2025 Results on Apr 29, 2026 Pulike Biological Engineering, Inc. announced that they will report fiscal year 2025 results on Apr 29, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.12 (up from CN¥0.10 in 3Q 2024). Revenue: CN¥263.6m (down 5.4% from 3Q 2024). Net income: CN¥41.0m (up 27% from 3Q 2024). Profit margin: 16% (up from 12% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 22% per year. Announcement • Sep 30
Pulike Biological Engineering, Inc. to Report Q3, 2025 Results on Oct 31, 2025 Pulike Biological Engineering, Inc. announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Jun 30
Pulike Biological Engineering, Inc. to Report First Half, 2025 Results on Aug 29, 2025 Pulike Biological Engineering, Inc. announced that they will report first half, 2025 results on Aug 29, 2025 Declared Dividend • Jun 07
Dividend of CN¥0.40 announced Shareholders will receive a dividend of CN¥0.40. Ex-date: 11th June 2025 Payment date: 11th June 2025 Dividend yield will be 2.7%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not covered by earnings (115% earnings payout ratio). However, it is covered by cash flows (55% cash payout ratio). The dividend has increased by an average of 12% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 28% to bring the payout ratio under control. EPS is expected to grow by 88% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.16 (vs CN¥0.08 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.16 (up from CN¥0.08 in 1Q 2024). Revenue: CN¥278.6m (up 18% from 1Q 2024). Net income: CN¥52.9m (up 94% from 1Q 2024). Profit margin: 19% (up from 12% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Apr 25
Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2025 Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: 2F, No. 15, Zhenghe Road, Luolong District, Luoyang, Henan China Price Target Changed • Apr 16
Price target decreased by 16% to CN¥15.13 Down from CN¥17.99, the current price target is an average from 2 analysts. New target price is 17% above last closing price of CN¥12.89. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥0.46 for next year compared to CN¥0.50 last year. Announcement • Mar 28
Pulike Biological Engineering, Inc. to Report Q1, 2025 Results on Apr 25, 2025 Pulike Biological Engineering, Inc. announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Dec 27
Pulike Biological Engineering, Inc. to Report Fiscal Year 2024 Results on Apr 25, 2025 Pulike Biological Engineering, Inc. announced that they will report fiscal year 2024 results on Apr 25, 2025 New Risk • Nov 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 46% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.4% net profit margin). Board Change • Nov 05
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Xian Sheng Zhang was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. New Risk • Oct 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.5% Last year net profit margin: 17% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 136% Cash payout ratio: 318% Minor Risk Profit margins are more than 30% lower than last year (9.5% net profit margin). Announcement • Sep 30
Pulike Biological Engineering, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Pulike Biological Engineering, Inc. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥12.97, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥14.81 per share. Buy Or Sell Opportunity • Sep 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to CN¥11.77. The fair value is estimated to be CN¥14.81, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 106% in the next 2 years. Price Target Changed • Aug 31
Price target decreased by 13% to CN¥16.24 Down from CN¥18.56, the current price target is an average from 4 analysts. New target price is 32% above last closing price of CN¥12.33. Stock is down 44% over the past year. The company is forecast to post earnings per share of CN¥0.60 for next year compared to CN¥0.50 last year. Buy Or Sell Opportunity • Aug 05
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 29% to CN¥12.26. The fair value is estimated to be CN¥15.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 108% in the next 2 years. Price Target Changed • Jul 10
Price target decreased by 8.3% to CN¥18.56 Down from CN¥20.24, the current price target is an average from 4 analysts. New target price is 49% above last closing price of CN¥12.45. Stock is down 45% over the past year. The company is forecast to post earnings per share of CN¥0.65 for next year compared to CN¥0.50 last year. Announcement • Jun 28
Pulike Biological Engineering, Inc. to Report First Half, 2024 Results on Aug 30, 2024 Pulike Biological Engineering, Inc. announced that they will report first half, 2024 results on Aug 30, 2024 Declared Dividend • Jun 11
Dividend of CN¥0.40 announced Shareholders will receive a dividend of CN¥0.40. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 4.6%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not covered by earnings (178% earnings payout ratio) nor is it covered by cash flows (dividend approximately 79x free cash flows). The dividend has increased by an average of 23% per year over the past 8 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 98% to bring the payout ratio under control. EPS is expected to grow by 107% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Valuation Update With 7 Day Price Move • May 28
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥19.22, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.63 per share. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥20.98, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 4.5% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.63 per share. Buy Or Sell Opportunity • May 13
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 25% to CN¥20.98. The fair value is estimated to be CN¥16.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 102% in the next 2 years. Major Estimate Revision • May 02
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥1.60b to CN¥1.39b. EPS estimate fell from CN¥0.907 to CN¥0.608 per share. Net income forecast to grow 65% next year vs 28% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥22.60 to CN¥20.24. Share price fell 2.6% to CN¥17.43 over the past week. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.19 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.08 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥235.5m (down 23% from 1Q 2023). Net income: CN¥27.3m (down 58% from 1Q 2023). Profit margin: 12% (down from 21% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Apr 27
Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024 Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024, at 14:00 China Standard Time. Location: 2F, No. 15, Zhenghe Road, Luolong District, Luoyang, Henan China Announcement • Mar 29
Pulike Biological Engineering, Inc. to Report Q1, 2024 Results on Apr 26, 2024 Pulike Biological Engineering, Inc. announced that they will report Q1, 2024 results on Apr 26, 2024 Price Target Changed • Mar 07
Price target decreased by 8.0% to CN¥25.07 Down from CN¥27.23, the current price target is an average from 3 analysts. New target price is 56% above last closing price of CN¥16.10. Stock is down 45% over the past year. The company is forecast to post earnings per share of CN¥0.70 for next year compared to CN¥0.54 last year. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥13.88, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 15x in the Pharmaceuticals industry in China. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥15.32 per share. Announcement • Dec 30
Pulike Biological Engineering, Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024 Pulike Biological Engineering, Inc. announced that they will report fiscal year 2023 results on Apr 26, 2024 Announcement • Nov 16
Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares. Pulike Biological Engineering, Inc. (SHSE:603566) ) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price of CNY 30 per share. The repurchases will be sourced from company’s own funds: The shares will be repurchased for equity incentives and/or employee stock ownership plans. The program will be valid for 12 months. Announcement • Sep 30
Pulike Biological Engineering, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Pulike Biological Engineering, Inc. announced that they will report Q3, 2023 results on Oct 26, 2023 Price Target Changed • Sep 01
Price target decreased by 7.9% to CN¥28.23 Down from CN¥30.67, the current price target is an average from 3 analysts. New target price is 28% above last closing price of CN¥22.09. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥0.73 for next year compared to CN¥0.54 last year. New Risk • Aug 31
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Announcement • Jun 28
Pulike Biological Engineering, Inc. to Report First Half, 2023 Results on Aug 30, 2023 Pulike Biological Engineering, Inc. announced that they will report first half, 2023 results on Aug 30, 2023 Major Estimate Revision • May 03
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from CN¥0.871 to CN¥0.777. Revenue forecast unchanged from CN¥1.41b at last update. Net income forecast to grow 47% next year vs 27% growth forecast for Pharmaceuticals industry in China. Consensus price target of CN¥30.50 unchanged from last update. Share price was steady at CN¥26.58 over the past week. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.19 (up from CN¥0.12 in 1Q 2022). Revenue: CN¥305.6m (up 25% from 1Q 2022). Net income: CN¥65.5m (up 75% from 1Q 2022). Profit margin: 21% (up from 15% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Price Target Changed • Nov 16
Price target decreased to CN¥28.05 Down from CN¥31.05, the current price target is an average from 2 analysts. New target price is 6.1% below last closing price of CN¥29.86. Stock is up 57% over the past year. The company is forecast to post earnings per share of CN¥0.65 for next year compared to CN¥0.78 last year. Major Estimate Revision • Nov 04
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from CN¥0.79 to CN¥0.67 per share. Revenue forecast steady at CN¥1.18b. Net income forecast to grow 113% next year vs 36% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥31.05 to CN¥28.05. Share price rose 22% to CN¥30.41 over the past week. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥30.41, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 34% over the past three years. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.21 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.16 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥313.0m (up 30% from 3Q 2021). Net income: CN¥52.6m (down 22% from 3Q 2021). Profit margin: 17% (down from 28% in 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 12
Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.24 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.14 (down from CN¥0.24 in 2Q 2021). Revenue: CN¥267.4m (down 1.2% from 2Q 2021). Net income: CN¥42.7m (down 44% from 2Q 2021). Profit margin: 16% (down from 28% in 2Q 2021). Over the next year, revenue is forecast to grow 30%, compared to a 23% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 28% per year. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥33.70, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 172% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥65.69 per share. Reported Earnings • Apr 30
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.12 (down from CN¥0.28 in 1Q 2021). Revenue: CN¥245.3m (down 21% from 1Q 2021). Net income: CN¥37.5m (down 57% from 1Q 2021). Profit margin: 15% (down from 28% in 1Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 30%, compared to a 24% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target decreased to CN¥22.55 Down from CN¥32.03, the current price target is an average from 3 analysts. New target price is 15% above last closing price of CN¥19.54. Stock is down 10% over the past year. The company is forecast to post earnings per share of CN¥0.87 for next year compared to CN¥0.72 last year. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥29.21, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 128% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥11.69 per share. Price Target Changed • Feb 08
Price target decreased to CN¥26.37 Down from CN¥32.03, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of CN¥25.66. Stock is up 13% over the past year. The company is forecast to post earnings per share of CN¥0.92 for next year compared to CN¥0.72 last year. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥25.35, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 114% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.27 per share. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥21.91, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 90% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.70 per share. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥241.8m (up 7.1% from 3Q 2020). Net income: CN¥67.0m (up 66% from 3Q 2020). Profit margin: 28% (up from 18% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 30
Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.20 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥270.5m (up 18% from 2Q 2020). Net income: CN¥76.8m (up 27% from 2Q 2020). Profit margin: 28% (up from 27% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 04
First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.18 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥308.7m (up 60% from 1Q 2020). Net income: CN¥86.8m (up 46% from 1Q 2020). Profit margin: 28% (down from 31% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Mar 16
New 90-day low: CN¥20.02 The company is down 11% from a price of CN¥22.40 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Lagged the Pharmaceuticals industry, which is down 8.0% over the same period. Simply Wall St's valuation model estimates the intrinsic value at CN¥10.27 per share. Reported Earnings • Mar 09
Full year 2020 earnings released: EPS CN¥0.68 (vs CN¥0.34 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥928.5m (up 40% from FY 2019). Net income: CN¥216.7m (up 98% from FY 2019). Profit margin: 23% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Mar 09
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 23%, compared to a 603% growth forecast for the Pharmaceuticals industry in China. Is New 90 Day High Low • Jan 19
New 90-day low: CN¥20.15 The company is down 24% from its price of CN¥26.41 on 21 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.27 per share. Is New 90 Day High Low • Dec 29
New 90-day low: CN¥21.50 The company is down 15% from its price of CN¥25.15 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.27 per share. Is New 90 Day High Low • Dec 09
New 90-day low: CN¥23.20 The company is down 6.0% from its price of CN¥24.73 on 10 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥10.44 per share. Is New 90 Day High Low • Nov 13
New 90-day low: CN¥23.82 The company is down 20% from its price of CN¥29.65 on 14 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥10.44 per share. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥174.6m, up 56% from the prior year. Total revenue was CN¥839.7m over the last 12 months, up 30% from the prior year. Announcement • Jul 18
Pulike Biological Engineering, Inc. to Report First Half, 2020 Results on Aug 31, 2020 Pulike Biological Engineering, Inc. announced that they will report first half, 2020 results on Aug 31, 2020